Recombinant Antibody

Recombinant Antibodies are immunoglobulin molecules produced through genetic engineering techniques rather than traditional hybridoma technology, offering superior control over antibody structure, function, and manufacturing consistency. This approach enables precise molecular design and scalable production in host organisms, revolutionising both therapeutic development and research applications across the biopharmaceutical landscape.

Scientists generate recombinant antibodies by cloning antibody gene sequences into expression vectors introduced into mammalian, bacterial, yeast, or plant cell systems. This methodology allows researchers to modify antibody characteristics systematically, including humanising mouse antibodies to reduce immunogenicity, engineering Fc regions to enhance effector functions, or creating bispecific formats that simultaneously bind multiple targets. The ability to store antibody sequences digitally and reproduce them reliably eliminates instability associated with hybridoma cell lines. The therapeutic antibody market, dominated by recombinant products, represents one of biotechnology's greatest commercial successes, with blockbuster drugs like adalimumab, pembrolizumab, and trastuzumab transforming treatment paradigms. Manufacturing facilities worldwide produce recombinant antibodies at kilogram scale using Chinese hamster ovary (CHO) cells. Emerging technologies including single B-cell cloning and phage display continue expanding the recombinant antibody toolkit, enabling rapid discovery of therapeutic candidates.